Humana Inc. reports news around its U.S. healthcare business, combining Humana insurance services with CenterWell healthcare services. Company updates commonly address Medicare Advantage and other health plan membership, Insurance segment benefit ratios, GAAP and adjusted earnings, full-year guidance, and capital returns through quarterly dividends.
News also covers CenterWell's senior-focused primary care, home health, pharmacy, hospice and retail pharmacy activities; prescription access and home delivery partnerships; healthcare research tied to medication adherence and chronic disease care; palliative care arrangements; health data interoperability; and board refreshment or other governance actions.
Humana (NYSE: HUM) released its 2024 Value-Based Care By the Numbers Report showing measurable benefits for Medicare Advantage members in value-based arrangements. Key findings include 24.3% fewer inpatient admissions versus Original Medicare, 13.4% fewer ED visits for MA value-based members, and a 13-point higher Net Promoter Score.
The report also shows stronger chronic disease management, higher preventive care rates, 20% more primary care visits for senior-focused patients, and improved clinician experience tied to coordinated, preventive models.
Zynex (ZYXIQ) announced a new in-network provider agreement with Humana (HUM), effective February 1, 2026.
The agreement brings Zynex electrotherapy products, including NexWave™, into Humana Medicare-PPO, POS, PFFS, HMO and multiple state Medicaid plans, expanding patient access nationwide; terms were not disclosed.
Humana (NYSE: HUM) launched Agent Assist, a Google Cloud–built AI solution to help 20,000+ member advocates deliver faster, more personalized support across benefit and eligibility questions. Agent Assist uses Vertex AI, Gemini and Gemini Enterprise for CX, began pilot use in October 2025, and will fully roll out across service centers in 2026.
The tool summarizes calls in real time, surfaces relevant information, provides compliance guidance, and preserves a human-in-the-loop approach aligned with Humana's Responsible AI principles.
Humana (NYSE: HUM) launched a $3 million Humana Health Workforce Scholarship Fund to provide annual full‑tuition scholarships for incoming medical students at Xavier Ochsner College of Medicine (XOCOM) to address physician shortages and expand access to care in Louisiana. Scholarships target students with financial need who commit to practice in primary care, internal medicine, or maternal care in Louisiana after graduation. The fund builds on Humana’s prior support for Xavier’s Physician Assistant program and complements broader Humana investments in digital medicine, recovery services, food security, and senior well‑being across Louisiana. Humana serves 203,000 Medicare Advantage and 120,000 Medicaid beneficiaries in Louisiana (as of Sept. 30, 2025).
Humana (NYSE: HUM) is partnering with Atlas Oncology Partners to expand coordinated oncology care for eligible Medicare Advantage members in Tennessee and Mississippi, effective Jan. 1, 2026. The program places interdisciplinary teams—oncologists, nurses, social workers, patient navigators—and offers virtual urgent care, palliative and psychosocial support, same-day or next-day appointments, and cancer-adjacent condition management to reduce gaps in care and unnecessary emergency visits.
The model emphasizes integrated clinician communication, real-time patient support, and advanced supportive care to prioritize quality of life and care coordination for seniors.
CenterWell Pharmacy (NYSE: HUM) will dispense Eli Lilly obesity management medicines through a new, employer-focused program administered by independent third-party administrators, supporting eligible patients in approved employer plan-sponsored carve-outs. CenterWell will handle prescription fulfillment and delivery and work with designated third-party organizations to expand access via employer benefits. The initiative emphasizes employer-focused distribution as a complement to prior direct-to-patient efforts and aligns with CenterWell's pharmacy and patient-care services.
Humana (NYSE: HUM) will release fourth quarter 2025 results and prepared remarks at 6:00 a.m. ET on February 11, 2026, followed by a live Q&A at 8:00 a.m. ET to discuss results and 2026 guidance. A live webcast will be available via the company’s Investor Relations page and a virtual archive will appear in Historical Webcasts roughly two hours after the live event. The earnings release will include non‑GAAP measures with a reconciliation to GAAP and management’s rationale, available on the Investor Relations page on February 11, 2026.
Humana (NYSE:HUM) announced a partnership with the Nurses on Boards Coalition to fund and launch the Mentoring for Success program in early 2026. Humana provided a first-year gift of $110,000 to match 50 nursing students with 50 Humana nurse mentors, then will continue funding at $90,000 per year. Humana becomes a founding partner with a leadership seat on the program advisory board impact group.
The program will use a secure virtual platform for mentor-mentee matching, scheduling, progress tracking, and community resources, and includes a NOBC micro-learning module on Language and Communication in the Boardroom.
Humana Foundation (HUM) published a report titled “Strengthening Belonging for Underserved Boys” on December 17, 2025, examining loneliness and mental health among boys from racially and ethnically diverse backgrounds, rural areas, LGBTQ+ identities, and those with differing abilities.
The report cites a Gallup poll finding 25% of American males aged 15–34 felt lonely “a lot” the previous day, notes boys are less often diagnosed with depression yet more likely to die by suicide, and highlights disparities for underserved groups. It recommends five actions including strategic communications, community-rooted outreach, scaled mentorship, peer mental health programs, and more research.
Humana (NYSE: HUM) received affirmed credit ratings from AM Best on Dec 16, 2025: the Humana Health Group FSR was affirmed at A (Excellent) with a stable outlook, while Humana Inc. long-term issuer credit ratings were affirmed at bbb (Good) with a stable outlook; short-term ratings were affirmed at AMB-2. AM Best noted adequate balance sheet strength, near double-digit CAGR capital growth over five years, and material support for Puerto Rico entities. AM Best highlighted ongoing Medicare Advantage (MA) pressures, Puerto Rico operating losses and elevated leverage as key considerations.